PAD-IN-2 is a potent pad4 inhibitor (IC50: <1 μM). PAD-IN-2 can be used in the research of auto-immune diseases and cancers, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cystic fibrosis, asthma, multiple sclerosis and psoriasis[1].
PAD-IN-2 (Example-57, 1 h) inhibits PAD4 activity with an IC50 value <1 μM (determined by ammonia release biochemical assay)[1].
[1]. Hallur, Gurulingappa, et al. Heterocyclic compounds as pad4 inhibitors. Patent WO2019058393 A1.
















